The U.S. Food and Drug Administration approved AbbVie’s Dalvance (dalbavancin) for acute bacterial skin and skin structure infections in pediatric patients as young as newborns.
Scientists are working on a benchmark for Covid-19 vaccine efficacy that would allow drugmakers to conduct smaller, speedier human trials to get them to market and address a huge global vaccine shortage.
Tokyo Olympics organizers on July 18 reported the first Covid-19 cases among competitors residing in the athletes’ village, as its population swells ahead of the start of the pandemic-hit Games.
Gilead Sciences Inc. announced new results from the Phase 2/3 CAPELLA trial evaluating lenacapavir, the company’s investigational, long-acting HIV-1 capsid inhibitor, in heavily treatment-experienced people living with multi-drug resistant HIV.
The U.S. Food and Drug Administration approved Merck’s Vaxneuvance (Pneumococcal 15-valent Conjugate Vaccine) for active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in adults 18 years of age and older.
U.S. Surgeon General Vivek Murthy raised the alarm on July 15 over a growing wave of misinformation about Covid-19 and related vaccines that threatens efforts to quell the pandemic and save lives, urging technology companies and others to act.
Data from a mid-stage clinical study of an experimental vaccine candidate developed by Affinivax and Astellas Pharma for Streptococcus pneumoniae shows ASP3772 is well tolerated and generated an antibody response against the deadly bacterial infection.
Los Angeles-based biopharmaceutical firm Enochian BioSciences received a green light from the U.S. Food and Drug Administration for feedback on a possible cure for infections caused by the hepatitis B virus (HBV).
The Olympics will take place without spectators in host city Tokyo, organizers said on July 8, as a resurgent coronavirus forced Japan to declare a state of emergency in the capital that will run throughout the Games.
Valneva SE was awarded Breakthrough Therapy Designation for the company’s single-shot chikungunya vaccine candidate, VLA1553, by the U.S. Food and Drug Administration.